Drug Trial Radar · NCT01926782
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
803
Actual
Start
Sep 2013
Primary completion
Sep 2014
Study completion Apr 2015
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Aug 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.
Conditions
- Hypercholesterolemia
Interventions
Placebo (for alirocumab)Drug
Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
AlirocumabDrug
Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
StatinDrug
Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT AnalysisTime frame: From Baseline to Week 24
- Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)Time frame: From Baseline to Week 24
Locations
83 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Chandler, Arizona
Site not named
Goodyear, Arizona
Site not named
Carmichael, California
Site not named
Fresno, California
Site not named
West Hills, California
Site not named
Wildomar, California
Site not named
Colorado Springs, Colorado
Site not named
Golden, Colorado
Site not named
Boynton Beach, Florida
Site not named
Jacksonville, Florida
Site not named
Safety Harbor, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Meridian, Idaho
Site not named
Chicago, Illinois
Site not named
Gurnee, Illinois
Site not named
Evansville, Indiana
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
Monroe, Louisiana
Site not named
Auburn, Maine
Site not named
Methuen, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
Rochester, New York
Site not named
Farmville, North Carolina
Site not named
Greensboro, North Carolina
Site not named
Greenville, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Wilson, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Marion, Ohio
Site not named
Tulsa, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Wyomissing, Pennsylvania
Site not named
Knoxville, Tennessee
Site not named
Dallas, Texas
Site not named
Houston, Texas
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.